Get the Stockscreener App
109.73
4.24%
-4.86
Guardant Health Inc stock is traded at $109.73, with a volume of 1.60M.
It is down -4.24% in the last 24 hours and up +6.55% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$114.59
Open:
$114.86
24h Volume:
1.60M
Relative Volume:
0.65
Market Cap:
$14.25B
Revenue:
$902.57M
Net Income/Loss:
$-398.79M
P/E Ratio:
-34.15
EPS:
-3.2131
Net Cash Flow:
$-274.52M
1W Performance:
-5.20%
1M Performance:
+6.55%
6M Performance:
+147.87%
1Y Performance:
+127.37%
1-Day Range:
$109.25
$115.25
1-Week Range:
$109.25
$120.74
52-Week Range:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
109.73 | 14.88B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
608.02 | 234.41B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
224.54 | 166.52B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
687.74 | 55.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
239.76 | 41.05B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.87 | 38.54B | 6.95B | 1.30B | 1.15B | 4.5696 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Risk Analysis: Does Tripadvisor Inc have declining or rising EPSJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
Guardant Health Inc (GH) Shares Down 3.74% on Jan 28 - GuruFocus
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 23% Undervaluation? - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Guggenheim Raises Price Target on Guardant Health (GH) to $135 | GH Stock News - GuruFocus
Guardant Health: Look For Explosive Revenue Growth Ahead (NASDAQ:GH) - Seeking Alpha
Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH) - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Baillie Gifford & Co. Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH): Court Decision Offers Incremental Positive in Litigation - GuruFocus
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating - 富途资讯
Guardant Can Try Again To Nix Patent Tied To $83M Verdict - Law360
Wall Street Has a Positive Opinion on Guardant Health (GH) - Finviz
Guardant Health, Inc. $GH is Emerald Mutual Fund Advisers Trust's 8th Largest Position - MarketBeat
Insider Sell: Terilyn Monroe Sells 8,571 Shares of Guardant Heal - GuruFocus
Guardant Health CPO Monroe sells $977k in stock By Investing.com - Investing.com UK
Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock - MarketBeat
Guardant Health CPO Monroe sells $977k in stock - Investing.com
Avoiding Lag: Real-Time Signals in (GH) Movement - Stock Traders Daily
AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test - Law360
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Analysts turn more bullish on Guardant Health, Inc. (GH) as 2026 growth catalysts build - MSN
Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - marketscreener.com
FDA Approves Guardant Health's (GH) Diagnostic for Colorectal Ca - GuruFocus
FDA Approval Boosts Guardant Health (GH) with New Diagnostic Use - GuruFocus
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Yahoo Finance
Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC - MarketBeat
Guardant Health (NASDAQ:GH) Hits New 12-Month HighHere's Why - MarketBeat
Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? - Yahoo Finance
Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 - Insider Monkey
Inspire Advisors LLC Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build - Insider Monkey
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families in North Carolina - New Bern Live
Guardant Health (GH) Joins Forces with Merck for Oncology Advancements - GuruFocus
Guardant Health announces multi-year strategic collaboration agreement with Merck for companion diagnostics - BioSpectrum Asia
Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck - TradingView — Track All Markets
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Chartmill
Campbell & CO Investment Adviser LLC Makes New $1.19 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Revenue Growth - DirectorsTalk Interviews
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth - Seeking Alpha
Guardant Health stock hits 52-week high at 113.98 USD By Investing.com - Investing.com Nigeria
IPO Launch: How does Guardant Health Inc compare to its peersJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Guardant Health stock hits 52-week high at 113.98 USD - Investing.com India
Sumitomo Mitsui Trust Group Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence - PA Media
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group - Yahoo Finance
Guardant Health Announces Strong 2025 Preliminary Revenue Growth - The Globe and Mail
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):